export default function HexarelinOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Hexarelin stimulates GH release more powerfully than any other injectable compound in its class. The problem is your body adapts to it faster than any other GHRP &mdash; the response drops off significantly within weeks, and you have to stop entirely to get it back. It also has an unusual interaction with cardiac tissue that no other compound in this category shares, and what that means in practice is not well understood.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Average Person &mdash; GH-curious, researching injectables</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I saw Hexarelin described as the most potent GH-releasing peptide. If it&rsquo;s the strongest, shouldn&rsquo;t it be the best choice?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It does produce the largest GH spike in its class</strong><br />Hexarelin genuinely outperforms ipamorelin, GHRP-2, and GHRP-6 in terms of acute GH pulse amplitude. That part of the claim is accurate &mdash; it is the most potent by that measure.</li>
          <li><strong>A stronger GH signal sounds like it should produce better results</strong><br />The intuition that more GH means more benefit is understandable. If the goal is recovery, body composition, or anti-aging effects from GH, a bigger signal seems like it would work better.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The body adapts to hexarelin faster than any other GHRP &mdash; within 3&ndash;4 weeks of continuous use, the GH response can drop significantly as receptors become less sensitive. The potency advantage is temporary and then gone until you take weeks off. Meanwhile, hexarelin also raises cortisol alongside GH (same as GHRP-2), and has an unusual interaction with cardiac tissue that other GHRPs don&rsquo;t. Ipamorelin has a lower peak GH pulse but a stable response you can sustain. For someone just exploring GH compounds, hexarelin is not the place to start. Net: the &ldquo;most potent&rdquo; label is real but misleading as a recommendation; for sustainable use, ipamorelin wins clearly.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; cardiac recovery interest, short-cycle peak performance</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I read that hexarelin has cardioprotective effects from research. Is there a legitimate angle on using it for heart health, or is that just researcher-to-community hype?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The cardiac receptor research is real &mdash; hexarelin binds a cardiac receptor no other GHRP touches</strong><br />Hexarelin binds to CD36, a scavenger receptor expressed on heart cells. In heart failure models, this activity showed protective effects on cardiac function. It is the only GHRP with this activity, and the research is peer-reviewed, not just forum speculation.</li>
          <li><strong>For a structured short cycle, the peak GH pulse could matter</strong><br />An athlete who understands the tachyphylaxis issue and plans a strict 4-week cycle with mandatory off time could legitimately use the potency advantage during that window, rather than trying to run it continuously.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The cardiac research was done in diseased hearts, not healthy ones &mdash; and in rodents. Whether the CD36 binding in hexarelin is protective, neutral, or potentially problematic in healthy humans with normal cardiac function is genuinely unknown. &ldquo;Cardioprotective in heart failure models&rdquo; does not translate cleanly to &ldquo;good for your heart during heavy training.&rdquo; If you have any existing cardiac history, this specific uncertainty should push you firmly toward ipamorelin instead. Net: the cardioprotective angle is scientifically interesting but practically uncharacterized; cardiac history is a specific screening point with hexarelin that doesn&rsquo;t exist with other GHRPs.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; cardioprotective mechanism, GH pulse optimization</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;Hexarelin is the only GHRP with CD36 activity independent of the GH release. What&rsquo;s the mechanistic picture, and is there a protocol design where hexarelin makes sense over ipamorelin?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The dual mechanism &mdash; ghrelin receptor plus CD36 &mdash; is unique in the GHRP family</strong><br />CD36 binding by hexarelin occurs independently of GH release and has been shown to reduce cardiac fibrosis and improve heart function in animal heart failure models. Whether this represents a separate pharmacological opportunity or just an unknown risk is genuinely open. For a biohacker tracking cardiac biomarkers, it at least provides something potentially measurable.</li>
          <li><strong>Tachyphylaxis as a protocol design constraint, not a disqualifier</strong><br />For someone who has already extracted maximum value from sustained ipamorelin cycles and wants to explore peak-amplitude short-cycle protocols, hexarelin&rsquo;s pharmacology fits a specific niche: 3&ndash;4 week maximum-GH-pulse windows followed by mandatory 4&ndash;6 week washout. The tachyphylaxis is predictable and manageable if it&rsquo;s built into the protocol design from the start.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The cortisol and prolactin co-elevation with hexarelin is the same non-selective problem as GHRP-2 &mdash; it undermines recovery and body composition goals in a way that ongoing ipamorelin use avoids. The CD36 cardiac activity adds a second axis of uncertainty that is not present with any other GHRP. Taken together: hexarelin sits in a narrow niche where someone specifically wants the peak GH pulse amplitude on a short cycle, accepts the cortisol tradeoff, and has no cardiac risk factors that make the CD36 variable concerning. That is a real niche, but it is narrow. For most biohacker-level protocols, ipamorelin plus CJC-1295 provides better sustained GH output with a cleaner and better-characterized profile. Net: technically interesting, narrowly applicable, not a default GHRP choice at any experience level.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Hexarelin is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not a sustainable choice for ongoing protocols &mdash; tachyphylaxis makes continuous use lose effect</li>
              <li>Not a clean GH stimulator &mdash; cortisol and prolactin elevation same as GHRP-2</li>
              <li>Not appropriate for anyone with cardiac history &mdash; the CD36 activity is an uncharacterized variable</li>
              <li>Not &ldquo;the most potent&rdquo; in a way that translates to better outcomes &mdash; the advantage erodes within weeks</li>
              <li>Not the current community standard &mdash; ipamorelin replaced it for good reasons</li>
              <li>Not suitable for anyone with diabetes or insulin resistance</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>Highest acute GH pulse of any GHRP &mdash; the peak amplitude claim is accurate</li>
              <li>The only GHRP with CD36 cardiac receptor activity &mdash; a pharmacologically unique characteristic</li>
              <li>Cardioprotective effects in heart failure animal models are peer-reviewed and real</li>
              <li>Useful for structured short-cycle protocols where the tachyphylaxis is planned around</li>
              <li>Understanding hexarelin&rsquo;s limitations explains exactly why ipamorelin was designed to replace it</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
